These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20226635)

  • 21. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
    Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
    Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modified Augmented Renal Clearance score predicts rapid piperacillin and tazobactam clearance in critically ill surgery and trauma patients.
    Akers KS; Niece KL; Chung KK; Cannon JW; Cota JM; Murray CK
    J Trauma Acute Care Surg; 2014 Sep; 77(3 Suppl 2):S163-70. PubMed ID: 24770557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurotoxic Concentration of Piperacillin during Continuous Infusion in Critically Ill Patients.
    Quinton MC; Bodeau S; Kontar L; Zerbib Y; Maizel J; Slama M; Masmoudi K; Lemaire-Hurtel AS; Bennis Y
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28717035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept.
    Roberts JA; Ulldemolins M; Roberts MS; McWhinney B; Ungerer J; Paterson DL; Lipman J
    Int J Antimicrob Agents; 2010 Oct; 36(4):332-9. PubMed ID: 20685085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion.
    Buck C; Bertram N; Ackermann T; Sauerbruch T; Derendorf H; Paar WD
    Int J Antimicrob Agents; 2005 Jan; 25(1):62-7. PubMed ID: 15620828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inadequate antimicrobial prophylaxis during surgery: a study of beta-lactam levels during burn debridement.
    Dalley AJ; Lipman J; Venkatesh B; Rudd M; Roberts MS; Cross SE
    J Antimicrob Chemother; 2007 Jul; 60(1):166-9. PubMed ID: 17504805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study.
    van Zanten AR; Polderman KH; van Geijlswijk IM; van der Meer GY; Schouten MA; Girbes AR
    J Crit Care; 2008 Sep; 23(3):422-30. PubMed ID: 18725050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate.
    Lipsky BA; Giordano P; Choudhri S; Song J
    J Antimicrob Chemother; 2007 Aug; 60(2):370-6. PubMed ID: 17553812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy.
    Felton TW; Roberts JA; Lodise TP; Van Guilder M; Boselli E; Neely MN; Hope WW
    Antimicrob Agents Chemother; 2014 Jul; 58(7):4094-102. PubMed ID: 24798288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients.
    Viscoli C; Cometta A; Kern WV; Bock R; Paesmans M; Crokaert F; Glauser MP; Calandra T;
    Clin Microbiol Infect; 2006 Mar; 12(3):212-6. PubMed ID: 16451406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Serum level-adjusted dosage of once-daily aminoglycoside therapy in critical illness: results of a prospective study].
    Reimann IR; Meier-Hellmann A; Pfeifer R; Traut T; Schilling A; Stein G; Reinhart K; Hoffmann A
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1999 May; 34(5):288-95. PubMed ID: 10372218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients.
    Mar Fernández de Gatta MD; Victoria Calvo M; Ardanuy R; Domínguez-Gil A; Lanao JM; Moreno SR
    J Pharm Pharmacol; 2009 Jun; 61(6):759-66. PubMed ID: 19505366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections.
    Jhee SS; Kern JW; Burm JP; Yellin AE; Gill MA
    Pharmacotherapy; 1995; 15(4):472-8. PubMed ID: 7479200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements.
    Ulldemolins M; Martín-Loeches I; Llauradó-Serra M; Fernández J; Vaquer S; Rodríguez A; Pontes C; Calvo G; Torres A; Soy D
    J Antimicrob Chemother; 2016 Jun; 71(6):1651-9. PubMed ID: 26869692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial.
    Harter C; Schulze B; Goldschmidt H; Benner A; Geiss HK; Hoppe-Tichy T; Ho AD; Egerer G
    Bone Marrow Transplant; 2006 Feb; 37(4):373-9. PubMed ID: 16400334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel way to investigate the effects of plasma exchange on antibiotic levels: use of microdialysis.
    Roberts JA; Roberts MS; Robertson TA; Cross SE; Lipman J
    Int J Antimicrob Agents; 2008 Mar; 31(3):240-4. PubMed ID: 18054829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients?
    Eachempati SR; Hydo LJ; Shou J; Barie PS
    J Trauma; 2009 May; 66(5):1343-8. PubMed ID: 19430237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results of the North American trial of piperacillin/tazobactam compared with clindamycin and gentamicin in the treatment of severe intra-abdominal infections. Investigators of the Piperacillin/Tazobactam Intra-abdominal Infection Study Group.
    Eur J Surg Suppl; 1994; (573):61-6. PubMed ID: 7524798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
    Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
    Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections.
    Hou F; Li J; Gao L; Chen Y
    Chin Med J (Engl); 1998 Nov; 111(11):1039-43. PubMed ID: 11189212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.